
Divi's Laboratories Ltd. (DIVISLAB): Divis Laboratories Share Price Rises 2.26% to Rs 9,692.15 Today
Updated: 28 Oct 2026 • 11:59 am
Posted by:

Divis Laboratories Share Price rose 2.26% on 28 October 2026, with Divi's Laboratories Ltd. (DIVISLAB) last trading at Rs 9,692.15 against a previous close of Rs 9,478.00 as of 11:52:28 AM IST. The company carries a market capitalisation of Rs 2,40,780.00 crore and operates in the Pharmaceuticals & Drugs industry of the Healthcare sector.
Univest figures confirm the price action, but they do not point to a specific company trigger. What the figures do show is a stock that opened at Rs 9,474.95, touched a high of Rs 9,692.15 and a low of Rs 9,374.40, and has added Rs 214.15 per share on the day. Its P/E ratio of 86.02 sits well above the industry median of 30.74, and its ROE of 16.19% is above the industry median of 11.23%.
Divis Laboratories Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 9,692.15 |
| Previous Close | Rs 9,478 |
| Today's Move | Rs 214.15 (+2.26%) |
| Open | Rs 9,474.95 |
| High | Rs 9,692.15 |
| Low | Rs 9,374.4 |
| Market Capitalisation | Rs 2,40,780 crore |
| Market Cap Category | Large Cap |
Divi's Laboratories Ltd. (DIVISLAB) rose to Rs 9,692.15 from the previous close of Rs 9,478, a move of Rs 214.15 or 2.26%. The stock opened at Rs 9,474.95, reached a high of Rs 9,692.15, recorded a low of Rs 9,374.4.
Divis Laboratories Share Price Today stands at Rs 9,692.15 as of 11:52:28 AM IST, a gain of Rs 214.15 or 2.26% over the previous close of Rs 9,478.00. The stock opened at Rs 9,474.95, touched a high of Rs 9,692.15 and a low of Rs 9,374.40, a day range of Rs 317.75.
The Divis Laboratories Share Price Update shows the stock opened Rs 3.05 below its previous close and has since added another Rs 217.20 from the opening level. The current price matches the day high and sits Rs 317.75 above the day low, so the stock is trading at the top of its range. Divis Laboratories market cap stands at Rs 2,40,780.00 crore at this price, a figure that reflects company size rather than quality.
These Divis Laboratories Share Price Live readings will keep changing while the session is open. The next section turns to fundamental analysis.
Divi's Laboratories Ltd. (DIVISLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,40,780 crore |
| P/E Ratio | 86.02x |
| P/B Ratio | 14.25x |
| ROE | 16.19% |
| ROCE | 21.51% |
| EPS | Rs 110.18 |
| Book Value Per Share | Rs 665.36 |
| Dividend Yield | 0.32% |
Divi's Laboratories Ltd. (DIVISLAB) fundamental metrics show P/E 86.02x, P/B 14.25x, ROE 16.19%, ROCE 21.51%. Taken on their own, these numbers offer context rather than a trading signal.
Divi's Laboratories Ltd. has a market capitalisation of Rs 2,40,780 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 86.02x, P/B at 14.25x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.19% and ROCE of 21.51%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 110.18, book value per share of Rs 665.36, dividend yield of 0.32%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 30.74x, median ROE of 11.23%, median ROCE of 13.17%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 86.02x |
| Benchmark Median P/E | 30.74x |
| Benchmark Average P/E | 43.3x |
| Benchmark P/E Range | 3.21x to 577.05x |
| Company P/B Ratio | 14.25x |
| Benchmark Median P/B | 2.71x |
| Company ROE | 16.19% |
| Benchmark Median ROE | 11.23% |
| Company ROCE | 21.51% |
| Benchmark Median ROCE | 13.17% |
| Company Market Capitalisation | Rs 2,40,780 crore |
| Benchmark Median Market Cap | Rs 696.43 crore |
Divi's Laboratories Ltd. (DIVISLAB) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Divi's Laboratories Ltd. (DIVISLAB) has a P/E ratio of 86.02x, which is above the benchmark median of 30.74x, a difference of +179.83%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Divi's Laboratories Ltd. (DIVISLAB) has a ROE of 16.19%, which is above the benchmark median of 11.23%, a difference of +44.17%. Divi's Laboratories Ltd. (DIVISLAB) has a ROCE of 21.51%, which is above the benchmark median of 13.17%, a difference of +63.33%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,18,204.09 | 34.91 | 4.88 | 14.85 | 19.11 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,73,828.11 | 82.48 | 9.53 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,15,520.92 | 25.79 | 4.32 | 19.69 | 21.39 |
| Laurus Labs Ltd. | LAURUSLABS | 1,11,304.32 | 105.74 | 20.5 | 18.31 | 18.2 |
| Cipla Ltd. | CIPLA | 1,09,304.89 | 37.65 | 3.1 | 11.83 | 16 |
Divi's Laboratories Ltd. (DIVISLAB) has a P/E ratio of 86.02x compared with the displayed peer median of 37.65x. The comparison is relative and should not be read as a recommendation. Its ROE of 16.19% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 21.51% versus the displayed peer median of 19.11%, providing a capital-efficiency comparison. Divi's Laboratories Ltd. (DIVISLAB) has a market capitalisation of Rs 2,40,780 crore. Among the 5 peers shown, only 1 has a larger market capitalisation.
Why Investors Are Watching Divis Laboratories
- Price action: the stock is up 2.26% at Rs 9,692.15 and trades Rs 317.75 above the day low of Rs 9,374.40.
- Fundamentals: EPS of Rs 110.18, book value of Rs 665.36 and ROE of 16.19% frame the earnings base.
- Valuation: a P/E of 86.02 compares with an industry median of 30.74.
- Sector positioning: ROCE of 21.51% is well above the benchmark median of 13.17% across 199 companies.
- Peers: ROE of 16.19% is above two of the five listed peers in the comparison.
About Divis Laboratories
Divi's Laboratories Ltd. trades under the symbol DIVISLAB and operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry. That industry group is the benchmark Univest uses for the company, and it holds 199 companies, including Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Zydus Lifesciences, Laurus Labs and Cipla.
With a market capitalisation of Rs 2,40,780.00 crore, Divis Laboratories sits above the benchmark median of Rs 696.43 crore and the average of Rs 13,492.66 crore for the industry.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What is the Divis Laboratories share price today?
Ans. Divis Laboratories Share Price was Rs 9,692.15 as of 11:52:28 AM IST on 28 October 2026, up Rs 214.15 or 2.26% from the previous close of Rs 9,478.00, after the stock opened at Rs 9,474.95.
What are the day high and low for Divis Laboratories?
Ans. Divis Laboratories touched a day high of Rs 9,692.15 and a day low of Rs 9,374.40, a range of Rs 317.75. The stock last traded at Rs 9,692.15, which matches the high.
What is the market capitalisation of Divis Laboratories?
Ans. Divis Laboratories has a market capitalisation of Rs 2,40,780.00 crore. Across the 199 companies in its industry benchmark, the median market capitalisation is Rs 696.43 crore and the average is Rs 13,492.66 crore.
What is the Divis Laboratories P/E ratio?
Ans. The P/E ratio of Divis Laboratories is 86.02. The same-industry benchmark of 199 companies shows a median P/E of 30.74 and an average of 43.3, so the stock trades above both.
What are the ROE and ROCE of Divis Laboratories?
Ans. Divis Laboratories has a return on equity of 16.19% and a return on capital employed of 21.51%. The industry median ROE is 11.23% and the median ROCE is 13.17%, so both sit above the median.
What are the EPS and book value of Divis Laboratories?
Ans. Divis Laboratories reports EPS of Rs 110.18 and a book value per share of Rs 665.36. Its dividend yield is 0.32%, which is a historical measure of payout relative to the current share price.
How does the Divis Laboratories P/B ratio compare with the industry?
Ans. Divis Laboratories has a P/B ratio of 14.25. The industry median is 2.71 and the average is 3.99, while P/B across the 199-company benchmark ranges from negative 25.49 to 22.27.
Which peers are compared with Divis Laboratories?
Ans. Divis Laboratories is compared with Sun Pharmaceutical Industries, Torrent Pharmaceuticals, Zydus Lifesciences, Laurus Labs and Cipla. Its P/E of 86.02 is higher than Sun Pharmaceutical Industries at 34.91 and higher than Torrent Pharmaceuticals at 82.48.
Track Divis Laboratories Share Price on Univest
Use Divi's Laboratories Ltd. (DIVISLAB) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
Readers can track the Divis Laboratories Share Price live on Univest, along with fundamental ratios such as P/E, P/B, ROE and ROCE, 52-week levels and wider market insights. Univest keeps price updates, peer figures and sector benchmarks in one place, so the stock can be followed alongside other market movers during the session.
Recent Articles

Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
18 November 2026

V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
18 November 2026

Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
18 November 2026

Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Cummins India Share Price Slips to Rs 4,005 Near Its 52-Week Low: Margins Squeezed by Commodity Costs While Price Hikes Take a Quarter to Flow Through
V2 Retail Share Price Plunges 15% to a 52-Week Low of Rs 122.73 Then Rebounds to Close at Rs 141.61: What We Know, What We Do Not and the Numbers to Watch
Infosys Share Price Falls to Rs 1,108.80, Down 25.4% in a Year: How India's IT Bellwether Lost a Quarter of Its Value and What Investors Should Check Next
Nifty Bank 62,000: Index Closes at 62,038.65 After a Record 62,442.20, Up 24% From Its April Low as SBI Surges While HDFC Bank and Axis Bank Lag
Mahanadi Coalfields IPO Opens 19 November: Rs 129 to Rs 136 Price Band, Rs 8,981 Crore Offer for Sale and a Coal India Unit Valued at About 8.4 Times Earnings

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





